UCB (OTCMKTS:UCBJY) Upgraded at Zacks Research

Zacks Research upgraded shares of UCB (OTCMKTS:UCBJY) from a hold rating to a strong-buy rating in a report issued on Tuesday,Zacks.com reports.

Separately, Wolfe Research upgraded UCB to a “strong-buy” rating in a report on Monday, February 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Strong Buy”.

UCB Price Performance

UCBJY stock opened at $152.05 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. UCB has a 1 year low of $76.52 and a 1 year high of $168.76. The firm has a 50-day moving average of $153.30 and a 200 day moving average of $146.01.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.